Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2023-12-03 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
董事长、监事会主席、高级管理人员换届公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the change of the company's chairman, supervisory board chairman, and senior management personnel. It details the election and appointment of these individuals, their shareholdings, and compliance with relevant laws and company bylaws. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory certifications. This fits the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-12-03 Chinese
第四届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolution from the first meeting of the fourth Supervisory Board of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda, and voting results related to the election of the Supervisory Board chairman. There is no financial data, audit information, or detailed report content. It is a formal announcement of board/management changes, specifically about the Supervisory Board chairman election. Therefore, it fits the category of Board/Management Information (MANG). The document length is short and focused on governance changes, not a full report or financial disclosure.
2023-12-03 Chinese
2023年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2023 third extraordinary general meeting of shareholders of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, voting results on various proposals including amendments to management systems, election of board members and supervisors, and legal opinions on the meeting's legality. The document focuses on the voting results and changes in board and supervisory personnel. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or a dividend notice. The key content is the official announcement of voting results from a shareholders' meeting, including election of directors and supervisors. Therefore, the document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is over 5,000 characters and contains substantive voting data, so it is not a mere announcement of a report publication (RPA). Confidence is high given the clear voting results and meeting details provided.
2023-12-03 Chinese
关于聘任名誉董事长的公告
Board/Management Information Classification · 100% confidence The document is an announcement from Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the appointment of an honorary chairman. It details the background and contributions of Mr. Li Yong'an and the board's decision to appoint him as honorary chairman without the rights and obligations of a board director. There is no financial data, no mention of financial results, no regulatory filings, or report publications. The content clearly relates to a change in the company's board or senior management structure. Therefore, this fits the category of Board/Management Information (MANG). The document length is short and focused solely on this appointment, confirming it is not a report or announcement of a report publication.
2023-12-03 Chinese
国浩律师（南京）事务所关于江苏德源药业股份有限公司2023年第三次临时股东大会之法律意见书
Regulatory Filings
2023-12-03 Chinese
第三届董事会第二十三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the 23rd meeting of the third board of directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results on board member nominations, amendments to company policies, and plans for submitting these matters to the shareholders' meeting. The content focuses on board and management changes, nominations, and governance matters. There is no financial data, earnings information, or report publication notice. The document is not a full annual or interim report, nor is it a voting result announcement from a shareholder meeting. It is a board meeting resolution announcement related to board and management information. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is 3315 characters, which is consistent with a detailed board meeting announcement rather than a full report.
2023-11-13 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.